Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase II Trial Of 250 mg ZD1839 (IRESSA™) In Prostate Cancer Patients With Early Biochemical Failure Post Prostatectomy

NCT00265070 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00265070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00265070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase II Trial Of 250 mg ZD1839 (IRESSA™) In Prostate Cancer Patients With Early Biochemical Failure Post Prostatectomy
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2003
Completion date
August 31, 2011
Enrollment
80 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer